Biotech Oncology & Energy

demand / volume

“TRANSFORMERS products were driven by increased consumer demand stemming from the September 2024 theatrical release of Transformers One with our partners at Paramount.”

HAS 10-Q

product pipeline / R&D affecting expense

“Clinical trial costs by scientific modalities, by product and by product candidate were as follows (dollars in thousands): Three Months Ended March 31, Percent Change 2026 2025 Small molecules: Zanzalintinib $ 37,273 $ 41,120 -9 % Cabozantinib 4,324 9,983 -57 % Other small molecules 1,589 5,516 -71 % Total small molecules 43,186 56,619 -24 % Biotherapeutics 8,218 6,122 34 % Total clinical trial costs $ 51,404 $ 62,741 -18 % 31 Table of Contents T he decrease in research and development expenses for the three months ended March 31, 2026, as compared to the corresponding prior year period, was primarily related to decreases in clinical trial costs and manufacturing costs to support our development candidates (presented as part of other development costs), partially offset by an increase in drug discovery-related license and other collaboration costs.”

EXEL 10-Q

credit / rates affecting interest expense

“The decrease in Interest expense primarily reflects lower average borrowings as of the end of the third quarter of 2025 as compared to those outstanding as of the third quarter of 2024, partially offset by a higher average interest rate on the outstanding borrowings .”

HAS 10-Q